



## Memorandum

**To:** Rick Blum, MD, FACEP

**From:** Sonja R. Montgomery, CAE  
Governance Operations Director

**Date:** May 4, 2018

**Subj:** Amended Resolution 34(17) Generic Injectable Drug Shortages

The 2017 Council and the Board of Directors adopted Amended Resolution 34(17) Generic Injectable Drug Shortages:

RESOLVED, That ACEP work with other medical specialties and patient advocacy groups to achieve consensus on the root cause of the shortage of generic injectable drugs and educate our members, the general medical community, and the public on this critical issue and how to solve it; and be it further

RESOLVED, That ACEP work with other medical specialties and patient advocacy groups to seek Congressional legislative repeal of the Group Purchasing Organizations' safe-harbor protection.

Please let me know if you need any additional information.

### HEADQUARTERS

Post Office Box 619911  
Dallas, Texas 75261-9911

4950 W Royal Ln  
Irving, TX 75063-2524

972-550-0911  
800-798-1822  
www.acep.org

### BOARD OF DIRECTORS

Paul D. Kivela, MD, MBA, FACEP  
*President*

John J. Rogers, MD, CPE, FACEP  
*President-Elect*

Debra G. Perrina, MD, FACEP  
*Chair of the Board*

Viktor E. Friedman, MD, FACEP  
*Vice President*

Stephen H. Anderson, MD, FACEP  
*Secretary-Treasurer*

Rebecca B. Parker, MD, FACEP  
*Immediate Past President*

James J. Augustine, MD, FACEP

Alison J. Haddock, MD, FACEP

Jon Mark Hirston, MD, PhD, MPH, FACEP

William P. Jagus, MD, FACEP

Christopher S. Kang, MD, FACEP

Kevin M. Klausner, DO, EJD, FACEP

Aisha T. Liferidge, MD, MPH, FACEP

Mark S. Rosenberg, DO, MBA, FACEP

Gillian R. Schmitz, MD, FACEP

### COUNCIL OFFICERS

John G. McManus, Jr, MD, MBA, FACEP  
*Speaker*

Gary R. Katz, MD, MBA, FACEP  
*Vice Speaker*

### EXECUTIVE DIRECTOR

Dean Wilkerson, JD, MBA, CAE